Page 23 - TD-4-3

Tumor Discovery FBXW7 in Leukemia

doi: 10.1073/pnas.0402770101 114. Janitri V, ArulJothi KN, Ravi Mythili VM, et al. The
roles of patient-derived xenograft models and artificial
107. Dye KN, Welcker M, Clurman BE, Roman A, intelligence toward precision medicine. MedComm (2020).
Galloway DA. Merkel cell polyomavirus Tumor antigens 2024;5(10):e745.
expressed in Merkel cell carcinoma function independently
of the ubiquitin ligases Fbw7 and beta-TrCP. PLoS Pathog. doi: 10.1002/mco2.745
2019;15(1):e1007543. 115. Burton AJ, Hamza GM, Zhang AX, Muir TW. Chemical
doi: 10.1371/journal.ppat.1007543 biology approaches to study histone interactors. Biochem
Soc Trans. 2021;49(5):2431-2441.
108. Jain N, Croner LJ, Allan JN, et al. Absence of BTK, BCL2, and
PLCG2 mutations in chronic lymphocytic leukemia relapsing doi: 10.1042/BST20210772
after first-line treatment with fixed-duration ibrutinib plus 116. Ihara H, Aoki Y, Aoki T, Toyoda M. Binding of bilirubin to
venetoclax. Clin Cancer Res. 2024;30(3):498-505. serum albumin in Crigler-Najjar syndrome, type I. Rinsho
doi: 10.1158/1078-0432.CCR-22-3934 Byori. 1986;34(9):1075-1078.
109. Tong J, Tan S, Nikolovska-Coleska Z, Yu J, Zou F, Zhang L. 117. King B, Trimarchi T, Reavie L, et al. The ubiquitin ligase
FBW7-Dependent Mcl-1 degradation mediates the FBXW7 modulates leukemia-initiating cell activity by
anticancer effect of Hsp90 inhibitors. Mol Cancer Ther. regulating MYC stability. Cell. 2013;153(7):1552-1566.
2017;16(9):1979-1988. doi: 10.1016/j.cell.2013.05.041
doi: 10.1158/1535-7163.MCT-17-0032 118. Niu M, Wang N, Yang D, et al. Multi-omics integration
reveals immune hallmarks and biomarkers associated with
110. Zhou C, Yang S, Wang J, et al. Recent advances in PROTAC- FLT3 inhibitor sensitivity in FLT3-mutated AML. Blood Sci.
based antiviral and antibacterial therapeutics. Bioorg Chem. 2025;7(2):e00227.
2025;160:108437.
doi: 10.1097/BS9.0000000000000227
doi: 10.1016/j.bioorg.2025.108437
119. Ayyadevara V, Wertheim G, Gaur S, et al. DYRK1A
111. Cornu M, Lemaitre T, Kieffer C, Voisin-Chiret AS. PROTAC inhibition results in MYC and ERK activation rendering
2.0: Expanding the frontiers of targeted protein degradation. KMT2A-R acute lymphoblastic leukemia cells sensitive to
Drug Discov Today. 2025;30:104376. BCL2 inhibition. Leukemia. 2025;39(5):1078-1089.
doi: 10.1016/j.drudis.2025.104376 doi: 10.1038/s41375-025-02575-w
112. Wang Y, Deng S, Xu J. Proteasomal and lysosomal degradation 120. Tantawy SI, Timofeeva N, Sarkar A, Gandhi V. Targeting
for specific and durable suppression of immunotherapeutic MCL-1 protein to treat cancer: opportunities and challenges.
targets. Cancer Biol Med. 2020;17(3):583-598. Front Oncol. 2023;13:1226289.

doi: 10.20892/j.issn.2095-3941.2020.0066 doi: 10.3389/fonc.2023.1226289
113. Li L, Wazir J, Huang Z, Wang Y, Wang H. A comprehensive 121. Li JY, Zuo LP, Xu J, Sun CY. Clinical applications of
review of animal models for cancer cachexia: Implications circulating tumor DNA in hematological malignancies:
for translational research. Genes Dis. 2024;11(6):101080. From past to the future. Blood Rev. 2024;68:101237.
doi: 10.1016/j.gendis.2023.101080 doi: 10.1016/j.blre.2024.101237

Volume 4 Issue 3 (2025) 15 doi: 10.36922/TD025150027